Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility
AssigneeTakeda Chemical Industries, Ltd.
InventorsYasuo Ohno, Tadashi Makino, Junichi Kikuta
Life of this patent
Estimating the term…
Abstract
A solid pharmaceutical preparation comprising a pharmaceutically active ingredient, erythritol, crystalline cellulose and an disintegrants, which exhibits a fast buccal disintegratability and dissolubility.
Claims18
A solid pharmaceutical preparation comprising (i) a pharmaceutically active substance, (ii) erythritol, (iii) crystaline cellulose and (iv) crospovidone.
A solid pharmaceutical preparation capable of buccal disintegration or dissolution, which comprises 0.3-50 parts by weight of (i) pharmaceutically active ingredient, 50-80 parts by weight of (ii) erythritol, and 5-20 parts by weight of (iii) crystalline cellulose and 3-7 parts by weight of (iv) crospovidone.
A method of improving buccal disintegration or dissolution of a solid pharmaceutical preparation containing (i) a pharmaceutically active ingredient, which comprises incorporating (ii) erythritol, (iii) crystalline cellulose and (iv) crospovidone into the solid pharmaceutical preparation.
A method of making a solid pharmaceutical preparation, which comprises:
- blending a mixture of (i) a pharmaceutically active ingredient, (ii) erythritol, (iii) crystalline cellulose and (iv) crospovidone, and producing the solid pharmaceutical preparation from the mixture.
A method of inhibiting or treating a disease of a subject in need thereof, which comprises administering to the subject an effective amount of (i) a pharmaceutically active ingredient for the disease as a solid pharmaceutical preparation containing (ii) erythritol, (iii) crystalline cellulose and (iv) crospovidone in addition to the pharmaceutically active ingredient (i), with an improved buccal disintegrability and/or dissolubility.
Dependencies are inferred from the claim text.